Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2009

01-04-2009 | Original Article

Ellagic Acid Inhibits Pancreatic Fibrosis in Male Wistar Bonn/Kobori Rats

Authors: Noriaki Suzuki, Atsushi Masamune, Kazuhiro Kikuta, Takashi Watanabe, Kennichi Satoh, Tooru Shimosegawa

Published in: Digestive Diseases and Sciences | Issue 4/2009

Login to get access

Abstract

The key pathological features of chronic pancreatitis are chronic inflammation, acinar atrophy, and pancreatic fibrosis. We have previously shown that ellagic acid, a plant-derived polyphenol found in fruits and nuts, inhibited activation of pancreatic stellate cells, a major profibrogenic cell type in the pancreas, in vitro. Here we examined whether ellagic acid inhibited the development of pancreatic fibrosis in vivo. Ellagic acid was administered orally in the diet to ten-week-old male Wistar Bonn/Kobori rats, an experimental model of spontaneous chronic pancreatitis, for ten weeks. Ellagic acid (100 mg/kg body weight/day) attenuated pancreatic inflammation and fibrosis. The protective effects were confirmed by an increase in pancreatic weight and decreases in myeloperoxidase activity (an index of neutrophil infiltration), collagen content, transforming growth factor-β1 expression, and the number of α-smooth muscle actin-positive cells (activated pancreatic stellate cells) and ED-1-positive cells (macrophages/monocytes). Ellagic acid inhibited the production of reactive oxygen species in pancreatic stellate cells in response to transforming growth factor-β1 or platelet-derived growth factor. Our results suggest that ellagic acid might be a candidate for treatment of chronic pancreatitis.
Literature
4.
go back to reference Talukdar R, Tandon R (2008) Pancreatic stellate cells: new target in the treatment of chronic pancreatitis. J Gastroenterol Hepatol 23:34–41PubMedCrossRef Talukdar R, Tandon R (2008) Pancreatic stellate cells: new target in the treatment of chronic pancreatitis. J Gastroenterol Hepatol 23:34–41PubMedCrossRef
5.
go back to reference Apte MV, Haber PS, Applegate TL, Norton ID, McCaughan GW, Korsten MA et al (1998) Periacinar stellate-shaped cells in rat pancreas: identification, isolation and culture. Gut 43:128–133PubMedCrossRef Apte MV, Haber PS, Applegate TL, Norton ID, McCaughan GW, Korsten MA et al (1998) Periacinar stellate-shaped cells in rat pancreas: identification, isolation and culture. Gut 43:128–133PubMedCrossRef
7.
go back to reference Masamune A, Kikuta K, Satoh M, Sakai Y, Satoh A, Shimosegawa T (2002) Ligands of peroxisome proliferator-activated receptor-γ block activation of pancreatic stellate cells. J Biol Chem. 277:141–147. doi:10.1074/jbc.M107582200 PubMedCrossRef Masamune A, Kikuta K, Satoh M, Sakai Y, Satoh A, Shimosegawa T (2002) Ligands of peroxisome proliferator-activated receptor-γ block activation of pancreatic stellate cells. J Biol Chem. 277:141–147. doi:10.​1074/​jbc.​M107582200 PubMedCrossRef
11.
go back to reference Kuno A, Yamada T, Masuda K, Ogawa K, Sogawa M, Nakamura S et al (2003) Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology 124:1010–1019. doi:10.1053/gast.2003.50147 PubMedCrossRef Kuno A, Yamada T, Masuda K, Ogawa K, Sogawa M, Nakamura S et al (2003) Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology 124:1010–1019. doi:10.​1053/​gast.​2003.​50147 PubMedCrossRef
12.
16.
go back to reference Thresiamma KC, Kuttan R (1996) Inhibition of liver fibrosis by ellagic acid. Indian J Physiol Pharmacol 40:363–366PubMed Thresiamma KC, Kuttan R (1996) Inhibition of liver fibrosis by ellagic acid. Indian J Physiol Pharmacol 40:363–366PubMed
20.
go back to reference Ohashi K, Kim JH, Hara H, Aso R, Akimoto T, Nakama K (1990) WBN/Kob rats. A new spontaneously occurring model of chronic pancreatitis. Int J Pancreatol 6:231–247PubMed Ohashi K, Kim JH, Hara H, Aso R, Akimoto T, Nakama K (1990) WBN/Kob rats. A new spontaneously occurring model of chronic pancreatitis. Int J Pancreatol 6:231–247PubMed
21.
go back to reference Tasaki M, Umemura T, Maeda M, Ishii Y, Okamura T, Inoue T et al (2008) Safety assessment of ellagic acid, a food additive, in a subchronic toxicity study using F344 rats. Food Chem Toxicol 46:1119–1124PubMed Tasaki M, Umemura T, Maeda M, Ishii Y, Okamura T, Inoue T et al (2008) Safety assessment of ellagic acid, a food additive, in a subchronic toxicity study using F344 rats. Food Chem Toxicol 46:1119–1124PubMed
22.
23.
go back to reference Sakthivel M, Elanchezhian R, Ramesh E, Isai M, Jesudasan CN, Thomas PA, Geraldine P (2008) Prevention of selenite-induced cataractogenesis in Wistar rats by the polyphenol, ellagic acid. Exp Eye Res 86:251–259PubMedCrossRef Sakthivel M, Elanchezhian R, Ramesh E, Isai M, Jesudasan CN, Thomas PA, Geraldine P (2008) Prevention of selenite-induced cataractogenesis in Wistar rats by the polyphenol, ellagic acid. Exp Eye Res 86:251–259PubMedCrossRef
25.
go back to reference Dolber PC, Spach MS (1993) Conventional and confocal fluorescence microscopy of collagen fibers in the heart. J Histochem Cytochem 41:465–469PubMed Dolber PC, Spach MS (1993) Conventional and confocal fluorescence microscopy of collagen fibers in the heart. J Histochem Cytochem 41:465–469PubMed
26.
go back to reference Yamanaka K, Saluja AK, Brown GE, Yamaguch Y, Hofbauer B, Steer ML (1997) Protective effects of prostaglandin E1 on acute lung injury of caerulein-induced acute pancreatitis in rats. Am J Physiol 272:G23–G30PubMed Yamanaka K, Saluja AK, Brown GE, Yamaguch Y, Hofbauer B, Steer ML (1997) Protective effects of prostaglandin E1 on acute lung injury of caerulein-induced acute pancreatitis in rats. Am J Physiol 272:G23–G30PubMed
27.
go back to reference Masamune A, Kikuta K, Satoh M, Kume K, Shimosegawa T (2003) Differential roles of signaling pathways for proliferation and migration of rat pancreatic stellate cells. Tohoku J Exp Med. 199:69–84. doi:10.1620/tjem.199.69 PubMedCrossRef Masamune A, Kikuta K, Satoh M, Kume K, Shimosegawa T (2003) Differential roles of signaling pathways for proliferation and migration of rat pancreatic stellate cells. Tohoku J Exp Med. 199:69–84. doi:10.​1620/​tjem.​199.​69 PubMedCrossRef
28.
go back to reference Bimmler D, Schiesser M, Perren A, Scheele G, Angst E, Meili S et al (2004) Coordinate regulation of PSP/reg and PAP isoforms as a family of secretory stress proteins in an animal model of chronic pancreatitis. J Surg Res 118:122–135. doi:10.1016/S0022-4804(03)00342-1 PubMedCrossRef Bimmler D, Schiesser M, Perren A, Scheele G, Angst E, Meili S et al (2004) Coordinate regulation of PSP/reg and PAP isoforms as a family of secretory stress proteins in an animal model of chronic pancreatitis. J Surg Res 118:122–135. doi:10.​1016/​S0022-4804(03)00342-1 PubMedCrossRef
31.
go back to reference Nagashio Y, Ueno H, Imamura M, Asaumi H, Watanabe S, Yamaguchi T et al (2004) Inhibition of transforming growth factor beta decreases pancreatic fibrosis and protects the pancreas against chronic injury in mice. Lab Invest 84:1610–1618. doi:10.1038/labinvest.3700191 PubMedCrossRef Nagashio Y, Ueno H, Imamura M, Asaumi H, Watanabe S, Yamaguchi T et al (2004) Inhibition of transforming growth factor beta decreases pancreatic fibrosis and protects the pancreas against chronic injury in mice. Lab Invest 84:1610–1618. doi:10.​1038/​labinvest.​3700191 PubMedCrossRef
34.
go back to reference Masamune A, Kikuta K, Satoh M, Suzuki N, Shimosegawa T (2005) Green tea polyphenol epigallocatechin-3-gallate blocks PDGF-induced proliferation and migration of rat pancreatic stellate cells. World J Gastroenterol 11:3368–3374PubMed Masamune A, Kikuta K, Satoh M, Suzuki N, Shimosegawa T (2005) Green tea polyphenol epigallocatechin-3-gallate blocks PDGF-induced proliferation and migration of rat pancreatic stellate cells. World J Gastroenterol 11:3368–3374PubMed
35.
38.
go back to reference Bala I, Bhardwaj V, Hariharan S, Sitterberg J, Bakowsky U, Kumar MNVR (2005) Design of biodegradable nanoparticles: a novel approach to encapsulating poorly soluble phytochemical ellagic acid. Nanotechnology 16:2819–2822. doi:10.1088/0957-4484/16/12/014 CrossRef Bala I, Bhardwaj V, Hariharan S, Sitterberg J, Bakowsky U, Kumar MNVR (2005) Design of biodegradable nanoparticles: a novel approach to encapsulating poorly soluble phytochemical ellagic acid. Nanotechnology 16:2819–2822. doi:10.​1088/​0957-4484/​16/​12/​014 CrossRef
39.
go back to reference Kasai K, Yoshimura M, Koga T, Arii M, Kawasaki S (2006) Effects of oral administration of ellagic acid-rich pomegranate extract on ultraviolet-induced pigmentation in the human skin. J Nutr Sci Vitaminol (Tokyo) 52:383–388. doi:10.3177/jnsv.52.383 CrossRef Kasai K, Yoshimura M, Koga T, Arii M, Kawasaki S (2006) Effects of oral administration of ellagic acid-rich pomegranate extract on ultraviolet-induced pigmentation in the human skin. J Nutr Sci Vitaminol (Tokyo) 52:383–388. doi:10.​3177/​jnsv.​52.​383 CrossRef
40.
go back to reference Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G (2005) Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Eur Urol 47:449–455. doi:10.1016/j.eururo.2004.12.001 PubMedCrossRef Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G (2005) Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Eur Urol 47:449–455. doi:10.​1016/​j.​eururo.​2004.​12.​001 PubMedCrossRef
Metadata
Title
Ellagic Acid Inhibits Pancreatic Fibrosis in Male Wistar Bonn/Kobori Rats
Authors
Noriaki Suzuki
Atsushi Masamune
Kazuhiro Kikuta
Takashi Watanabe
Kennichi Satoh
Tooru Shimosegawa
Publication date
01-04-2009
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-008-0423-7

Other articles of this Issue 4/2009

Digestive Diseases and Sciences 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine